BACKGROUND : Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-stimulating
factors (G-CSFs) can significantly reduce the risk of FN. International guidelines recommend G-CSF for ...
Filgrastim is approved for several indications, including reduction of the incidence and duration of chemotherapy-induced neutropenia and for stem cell mobilization. The filgrastim biosimilar, EP2006, has been available ...
Cancer care has been profoundly impacted by the global pandemic of severe acute respiratory syndrome coronavirus 2 disease (coronavirus disease 2019, COVID-19), resulting in unprecedented challenges. Supportive care is an ...
